

2016

## Detection of Antibiotic Resistance Clostridium difficile in Lettuce

Yi Han

*Louisiana State University and Agricultural and Mechanical College*

Follow this and additional works at: [https://repository.lsu.edu/gradschool\\_theses](https://repository.lsu.edu/gradschool_theses)



Part of the [Life Sciences Commons](#)

---

### Recommended Citation

Han, Yi, "Detection of Antibiotic Resistance Clostridium difficile in Lettuce" (2016). *LSU Master's Theses*. 1516.

[https://repository.lsu.edu/gradschool\\_theses/1516](https://repository.lsu.edu/gradschool_theses/1516)

This Thesis is brought to you for free and open access by the Graduate School at LSU Scholarly Repository. It has been accepted for inclusion in LSU Master's Theses by an authorized graduate school editor of LSU Scholarly Repository. For more information, please contact [gradetd@lsu.edu](mailto:gradetd@lsu.edu).

DETECTION OF ANTIBIOTIC RESISTANCE *CLOSTRIDIUM*  
*DIFFICILE* IN LETTUCE

A Thesis

Submitted to the Graduate Faculty of the  
Louisiana State University and  
Agricultural and Mechanical College  
in partial fulfillment of the  
requirements for the degree of  
Master of Science

in

The School of Nutrition and Food Sciences

by

Yi Han

B.S., Tongji University, 2013

August 2016

# TABLE OF CONTENTS

ACKNOWLEDGEMENTS .....	vi
ABSTRACT.....	vii
CHAPTER I. Introduction to <i>Clostridium difficile</i> .....	1
1.1 <i>Clostridium difficile</i> .....	1
1.2 History of <i>C. difficile</i> .....	1
1.3 Toxins of <i>C. difficile</i> .....	4
1.4 Sporulation of <i>C. difficile</i> .....	8
1.5 Epidemiology .....	10
1.6 Risk factors associated with CDI .....	11
1.7 Treatments for CDI .....	13
1.8 <i>C. difficile</i> in food .....	15
CHAPTER II. Detection of antibiotic resistance <i>C. difficile</i> in lettuce .....	17
2.1 Introduction .....	17
2.2 Materials and methods .....	19
2.2.1 Sample preparation .....	19
2.2.2 Isolation <i>C. difficile</i> .....	20
2.2.3 DNA Extraction .....	21
2.2.4 Real-time PCR assays for toxin A and B .....	21
2.2.5 Antibiotic resistance detection .....	23
2.3 Results and discussions .....	24
2.3.1 Isolation <i>C. difficile</i> .....	24
2.3.2 Real-time PCR assays for toxin A and B .....	25
2.3.3 Antibiotic resistance detection .....	29
2.4 Conclusion .....	30
REFERENCES .....	31
VITA .....	41

## LIST OF TABLES

Table 1. Primers and probes used for real-time PCR detection of <i>C. difficile</i> .....	21
Table 2. The <i>Clostridium difficile</i> Selective Agar (CDSA) test positive result of the lettuce samples from California, Arkansas, and Louisiana between September 2014 and March 2015.....	23
Table 3. The positive result from real-time PCR for toxin B detection of <i>C. difficile</i> isolates in California, Arkansas, and Louisiana between September 2014 and March 2015.....	25
Table 4. Real-time PCR profile of <i>C. difficile</i> isolates in lettuce samples among the states tested.....	27
Table 5. Susceptibility of the <i>C. difficile</i> isolates to 5 antibiotics.....	28

## LIST OF FIGURES

Figure 1. Pseudomembranous colitis. ....	2
Figure 2. The model of toxin A and toxin B.....	5
Figure 3 The pathogenicity locus.....	6
Figure 4. Stages of Sporulation.....	10
Figure 5. The growth temperature of the sample lettuces harvested from California, Arkansas, and Louisiana between September 2014 and March 2015.....	26

## ACKNOWLEDGEMENT

I would like to acknowledge Dr. Marlene E Janes, as my major advisor, for being so resourceful and helpful leading to my master degree acquirement. I would also like to express my sincere appreciates to my research committee, Dr. Joan M King and Dr. Jack N Losso, for their invaluable guidance and support during my research. I would also like to express my gratitude to my minor professor at LSU Department of Experimental Statistics, Dr. Bin Li, for teaching me statistical analysis techniques. I would like to acknowledge the department of Nutrition and Food Sciences for accepting me as a master student three year ago. I have gained marvelous experience and knowledge during this period. I also acknowledge all my labmates (past and present), Mr. Da Liu, Dr. Naim Montazeri, Dr. Morgan A Maite, Dr. Evelyn Gutierrez, Mr. Jose L Brandao, Ms. Katheryn J Parraga Estrada, Ms. Martha M Escoto Delgado, Ms. Dorra Simmons, and Mr. Mohammed Alhejaili, for all the help they provided.

Besides, I would also like to thank my family members, my boyfriend and friends for their support and love.

## ABSTRACT

*Clostridium difficile* (*C. difficile*) is regarded as the major cause of infectious diarrhea in humans after antimicrobial treatment. *C. difficile* has been reported to be widely isolated from food animals and meat. The main purpose of this study was to characterize *C. difficile* isolates from retail fresh vegetable (lettuce), test the antibiotic-resistance property using five common clinical-selected antibiotics (metronidazole, vancomycin, clindamycin, erythromycin, and cefotaxime). Lettuces (grown in California, Arkansas, and Louisiana) were purchased from retail stores. Toxigenic *C. difficile* was isolated from 13.8% (41/297) of the lettuce samples. Among the toxigenic isolates, 82.9% (34/41) only produce toxin B, and 17.1% (7/41) produced both toxin A and toxin B. Under the treatment of the five antibiotics, the virulence *C. difficile* isolates were identified as having antibiotic resistance to metronidazole, vancomycin, and erythromycin. The present study reports the highest toxigenic *C. difficile* yield rate from varieties of retail vegetables (lettuce) in the USA. The antibiotic resistance to metronidazole, vancomycin, and erythromycin of the isolated *C. difficile* from varieties of retail lettuces could lead to public health concerns.

## CHAPTER I. Introduction to *Clostridium difficile*

### 1.1 *Clostridium difficile*

*Clostridium difficile* (*C. difficile*), a species of Gram-positive, spore-forming, and anaerobic bacteria, causes diarrhea and more serious intestinal conditions such as pseudomembranous colitis in humans (Monaghan et al. 2013). The name given to this organism was because it was difficult to isolate and grew slowly when being cultured. According to the Center for Disease Control and Prevention (CDC), *C. difficile* has been listed as an immediate health threat, and *C. difficile* infection (CDI) induces 250,000 hospitalizations and 14,000 deaths per year. There are typically three manifestations of CDI development: asymptomatic carrier state, colitis with or without pseudomembranes, and fulminant colitis.


### 1.2 History of *C. difficile*

*C. difficile* was first identified in 1935 in the common intestinal colonic flora of newborn infants (Hall and O'Toole, 390-402). At first, it was known as *Bacillus difficile*, because it was difficult to grow outside of anaerobic broth culture. It was so frequently isolated from the feces of newborn infants that it was regarded as part of the infants' gut microbiota at that time. However, subsequent studies indicated its pure broth cultures could lead to experimental animal death if being injected (Snyder 1937). Thus, *C. difficile* was believed as non-pathogenic to humans. Not until the late 1970s were the biological activities of its toxins defined, and *C. difficile* toxins were linked



to pseudomembranous colitis (PMC), proving it to be a human pathogen(Bartlett et al. 1978a).

In 1893, the definition of pseudomembranous colitis (PMC) was first raised by Finney (Bartlett et al. 1978b) as a post-operative complication. PMC (Figure 1) is described as multiple yellow discrete patches (Figure 1) growing on the surface of colon mucosal (Nelson et al. 1994) ,which microscopically reveals partially destroyed



**Figure 1.** Pseudomembranous colitis.

mucosal layer glands covered with fibrin and inflammatory polymorph nuclear leukocytes (Nelson et al. 1994). The residues of colonic glands are able to become necrotic and inflamed. Besides, the submucosa may also become contaminated with the increasing amount of vasculature and inflammatory cells, which are responsible for water loss and subsequent diarrhea (Nelson et al. 1994). The pseudomembrane is considered as having the ability of growing over and replacing the normal colonic mucosa concerning bacterial toxins (Bartlett et al. 1978b).

PMC was not commonly diagnosed until the increasing usage of antimicrobial agents in the 1950s, when PMC was known as a common complication with high mortality rates (Nelson et al. 1994). At first, *Staphylococcus aureus* was regarded as

the reason to cause PMC by the Gram staining of plaques. Later, the stains revealed many Gram positive cocci in clusters (Bartlett et al. 1978b). This theory was also supported by the knowledge of staphylococcal enterotoxins produced by *S. aureus* causing enteric disease, and the clinical improvement when treating those patients suffering from PMC with vancomycin instead (Bartlett et al. 1978b). Because of the failure of imitating the effects that were occurring in humans using animal models infected with *S. aureus*, other potential causes of the origin of PMC were pursued continuously (Bartlett et al. 1978b). The true explanation of these infections stayed unknown, and was not being associated with *C. difficile* until two decades later when the connection between the toxins A and B of *C. difficile* and PMC was revealed (Bartlett et al. 1978b).

In the 1960s, anaerobic bacteria were related to the formation of aposteme, and several new antibiotics were developed to target them. Clindamycin was especially effective for intestinal infections caused by anaerobic bacteria (Bignardi 1998). However, there was a common side effect of clindamycin treatment---diarrhea, which some patients severely suffered from and progressed to PMC in a lot of cases (Bignardi 1998). This antibiotic-associated diarrhea was not only seen with clindamycin, but also with other broad spectrum antimicrobials, so it was named as antibiotic associated diarrhea (AAD) (Bignardi 1998). After *C. difficile* toxins were identified in patients suffering from colitis, the linkage among *C. difficile*, antibiotic usage and PMC was established (Bartlett et al. 1978b).

Based on the association of antimicrobial use, PMC and *C. difficile*, researchers began to exploring a toxin responsible for the diarrhea associated with *C. difficile* infection (CDI). First, toxin B was confirmed by neutralizing the toxin's effect by using the antitoxin of *Clostridium sordellii*. Toxin B was lethal in animal testing, the ability of causing severe hemorrhage, and mucosal edema in the cecum of laboratory animals. During the process of purifying the toxin, a second toxin showed up, toxin A. However, injecting an equal amount of toxin A followed by the same route was not lethal in animal models, and only brought about focal hemorrhage (Taylor, Thorne, and Bartlett 1981). Purified toxin A was able to result in a disease pathology similar to CDI, while testing animals in the same condition, toxin B had no effect at that time. Thus, Toxin B was thought to have an effect on test animals only with the presence of toxin A (Mitchell et al. 1986b, Taylor, Thorne, and Bartlett 1981). However, a toxin A negative, toxin B positive strain was isolated in a CDI outbreak in Canada in 1998, and later these strains have been discovered frequently (Drudy, Fanning, and Kyne 2007). So it has been regarded that both toxins are now considered responsible for the pathology, although toxin A positive, toxin B negative strains have not been found to be naturally present. In 2009, laboratory created toxin-A positive, toxin B-negative mutants showing reduced pathology in a hamster model, where pathology in hamsters caused by toxin A-negative, toxin B positive mutants remained unaffected in severity (Lyras, O'Connor, et al. 2009). This result indicates that toxin B


is essential for *C. difficile* disease, and synergy effect along with toxin A may not be necessary (Lyras, O'Connor, et al. 2009).

### **1.3 Toxins of *C. difficile***

Those strains lack of the ability of producing toxins are not considered pathogenic. When nutrients are abundant, toxin production will be inhibited, while during the essential nutrients shortage, particularly biotin, toxin production will cause intestinal epithelial cells to rupture, releasing nutrients (Yamakawa et al. 1996).

Pathogenic *C. difficile* produces two protein exotoxins, Toxin A, comprised of 2710 residues (308.0 kDa), and toxin B, comprised of 2366 residues (269.6 kDa) (Kelly and LaMont 1998). Toxin A and toxin B (also called TcdA and TcdB), belonging to the large clostridial cytotoxins (LCT), can cause animal death, while toxin A, called enterotoxin, has been proven to cause fluid accumulation, and severe epithelial damage with hemorrhage and diarrhea in rabbit ileal loops (Mitchell et al. 1986a, Torres and Lonroth 1989). After toxin A and toxin B gain access into cells, they exert an alteration of Rho proteins (a family of GTP-binding protein associated with actin polymerization, cytoskeletal architecture, and cell movement) and finally result in the depolymerization of actin filaments, disruption of the cytoskeleton, cell rounding, and cell death (Kelly and LaMont 1998). Both A and B toxins contain four domains (Figure 2): a receptor binding domain; an enzymatic domain; an autoproteolytic cleavage during toxin-processing domain; and a hydrophobic translocation domain responsible for transferring the enzymatic domain into the cytosol (Belyi and Aktories


2010). The C terminal receptor binding domains of the two toxins are different, allowing the toxins to attach to the corresponding intestinal epithelial cell receptors toxin A to the apical surface receptors, and toxin B to the basolateral surface receptors (Jank, Gieseemann, and Aktories 2007).



**Figure 2.** The model of toxin A and toxin B.

The genes encoding toxin A and toxin B are part of the pathogenicity locus (PaLoc), a 19.6kb chromosomal segment consists of TcdA-E genes (Figure 3) which provides a base for *C. difficile* PCR genotyping (Warny et al. 2005). These genes encode toxin A (TcdA), toxin B (TcdB), a negative regulator (TcdC), a positive regulator (TcdD), and a holing-like protein (TcdE). Transcription analysis studies indicate that TcdA, B, D, E are transcribed both monocistronically and polycistronically (Hundsberger et al. 1997). This mode of transcription is clearly the prior condition of a high production of toxin A and toxin B (Hundsberger et al. 1997). While, during the logarithmic phase, the TcdC gene has strong expression, and the other four genes are in weak transcription. The inverse is observed during the stationary phase, implicating that TcdC negatively regulates toxin expression (Hundsberger et al. 1997). Yet, the presence of TcdC genes, including TcdA and TcdB,

has also been found outside the PaLoc in several *C. difficile* strains. As TcdD increases with TcdA, B, E, TcdD is recognized as a positive regulation promoting toxin expression. Thus, TcdC and TcdD might be key factors regulating the production of the two toxins.



**Figure 3.** The pathogenicity locus.

Both toxins stay stable from -20 to 37<sup>0</sup>C, but will lose activity at 56<sup>0</sup>C (Sullivan, Pellett, and Wilkins 1982). Yet, neither toxin has effect on intracellular levels of cyclic AMP or GMP (Kelly and LaMont 1998). In addition, neither toxin is found to have association with spore production (Arnon et al. 1984). One of the physicochemical properties of toxin A, after purification, is its large size (Lyerly, Krivan, and Wilkins 1988). It can cause huge damage to gut mucosa (Mitchell et al. 1986a).

Toxin B, as a cytotoxin, is believed to be as lethal as toxin A, but less stable than toxin A (Arnon et al. 1984, Banno et al. 1984). It brings generous nonspecific responses in mammalian cells, such as the loss of intracellular potassium, decrease in protein synthesis, and decrease in synthesis of ribonucleic and deoxyribonucleic acids (Pothoulakis et al. 1986, Rihn et al. 1985). It induces rounding cells 100-10000 times more severe than toxin A in many cell types (Chaves-Olarte et al. 1997).

*C. difficile* transferase (CDT), a third toxin (aka, binary toxin), is an actin-specific ADP-ribosyltransferase; it was first proposed by Popoff et al. together with a few *C. difficile* strains in 1988 (Perelle et al. 1997, Popoff et al. 1988, Stubbs et al. 2000). Other similar toxins are produced by other species such as: iota toxin from *Clostridium perfringens* (Stiles and Wilkins 1986), *Clostridium botulinum* ADP-ribosyltransferase C3 (Aktories, Weller, and Chhatwal 1987), and *Clostridium spiroforme* toxin (CST) (Simpson et al. 1989). The CDT toxin structure is composed of two separate proteins encoded by genes *cdtA* and *cdtB*, where A is the enzyme component and B is the receptor binding and translocation component. Cells contaminated by CDT toxin present depolymerization of F actin, leading to cell rounding. Additionally, the formation of surface microtubules displays in these cells that have been shown to raise the possibility of *C. difficile* adherence. This increased adherence to the cell surfaces may promote colonization, adding to the virulence of these CDT producing strains (Schwan et al. 2009). It was shown that *C. difficile* strains which produce CDT toxin in addition to toxins A and B tend to be more virulent, especially the hypervirulent PCR ribotype 027 and 078 strains. Nonetheless, some *C. difficile* strains only produce CDT toxin without toxins A and B; there is no strong evidence indicating a hypervirulent strain (Stubbs et al. 2000).

#### **1.4 Sporulation of *C. difficile***


*C. difficile*'s ability to produce infectious endospores assists both its survivability outside and inside of its host. Sporulation forms when reproduction of

vegetative cells suffers from nutrient deprivation or undesirable conditions. The metabolically inactive property of the spores gives them the ability of being resistant to antimicrobial treatments, heat, radiation, desiccation and chemical treatments. Thus, spores are resistant to the majority of cleaning products used in healthcare facilities (Gerding, Muto, and Owens 2008). The spore formation of *C. difficile* grants the bacteria fecal oral transmission in healthcare facilities, either directly from patient to patient, or by transmission from the hands of health care personnel (Lawley et al. 2009, Underwood et al. 2009). Researchers found spores are frequently spread by flushing toilets or changing the bed sheets contaminated with feces from *C. difficile* patients (Best et al. 2010, Donskey 2010, Roberts et al. 2008).

Prokaryote sporulation is an evolutionary performance to protect species survival. Spore formation allows cells to wait until environmental conditions become suitable for them to switch back to their vegetative form and continue growing (De Hoon, Eichenberger, and Vitkup 2010). The process of sporulation has been thoroughly studied in *Bacillus subtilis*; its process may also be applied to *C. difficile*. Sporulation can be divided into seven separate stages (Figure 4). The process starts with stage I, where the vegetative cell grows in size and replicates its DNA followed normally by cell division resulting in stage 0. Different from a normal binary cell division, the cell is divided into two unequal parts called stage II during the sporulation process. The larger portion is considered as the mother cell, and the smaller portion is the fore spore. In stage III, the fore spore then becomes immersed in



the mother cell, continuing the process of growing to a mature spore at the same time. In stage IV, peptidoglycan forms the cortex layer of the fore pore, separating the two cells. Calcium dipicolinate synthesized by the mother cell is concentrated in the spore core, stabilizing the DNA. Dipicolinic acid and calcium enable the spore to become resistance to heat and oxidizing agents (Setlow 2007). During stage V, an outer protein layer is formed to coat the outer membrane. The spore turns to be mature in stage VI, along with finishing coat synthesis, dehydration, and lysis of the mother cell wall by the action of lytic proteins. Accordingly, the dormant spore is released (De Hoon, Eichenberger, and Vitkup 2010, Paredes, Alsaker, and Papoutsakis 2005).



**Figure 4.** Stages of Sporulation.

## **1.5 Epidemiology**

*C. difficile* infection stands in the first place in the cause of antibiotic associated diarrhea, having a percentage of 10-25% of all cases (Bartlett 2002). Carriage and colonization rates vary widely between different patient groups. Among the normal adult population, *C. difficile* asymptomatic carriage is estimated at 2-3%, but much higher in those frequently exposed to healthcare environments (Barbut and Petit 2001). Concerning the newborns, they are highly susceptible to acquiring *C. difficile*, given the fact that they have no protective normal gut flora to inhibit colonization. Normally, the acquisition of *C. difficile* in newborns is considered to be gained from the child's mother flora or the newborn nursery environment (TABAQCHALI et al. 1984). Carriage rates in newborns born in hospitals have been appeared to be as high as 70% (Kato et al. 1994, TABAQCHALI et al. 1984). Carriage rates are also showed to be higher in healthcare providers and high risk patients that have been hospitalized or received antibiotics (Barbut and Petit 2001, Giannasca and Warny 2004). It is reported that approximately one-third of the long-term healthcare facility residents asymptotically carry *C. difficile* (Simor et al. 2002).

## **1.6 Risk factors associated with *C. difficile* infection (CDI)**

The key risk factor associated with development of CDI is the treatment with antibiotics. More than 90% of all CDI cases happen during or following treatment with antibiotics (Barbut and Petit 2001). Apart from aminoglycosides, almost every

other antibiotic would lead to some risk of progression from asymptomatic colonization to CDI (Sunenshine and McDonald 2006). Exposure to antibiotics may develop to CDI, but the infection could be delayed for up to 8 weeks after antibiotics are consumed (Johnson and Gerding 1998b, Kelly, Pothoulakis, and LaMont 1994). A majority of CDI cases involved the use of clindamycin, fluoroquinolones, or third generation cephalosporins (Gerding 2004). It is supported that limiting the use of these antibiotics could significantly reduce the healthcare acquired infections (HAI) concerning *C. difficile* (Carling et al. 2003). It is vital for individual healthcare institutions to be aware of the sensitivity and resistance patterns of *C. difficile* isolates that rely on their environment and patient population. If an isolate in an institution shows its resistant to clindamycin, then the use of clindamycin should be highly restricted (Owens et al. 2008, Pear et al. 1994). On the other side, if a patient's *C. difficile* organisms are routinely sensitive to a specific antimicrobial, then the use of that antibiotic should be encouraged (Donskey 2010).

There are several high risk populations, whose who are the elderly, immune dysfunctional, pregnant, and those frequently exposed to healthcare environments. Patients older than 65 years of age or with severe underlying illness are vulnerable to CDI (Barbut and Petit 2001, Bignardi 1998). The reason of this may also be associated with more frequency of hospitalization, decreasing immune function, and an increased likelihood to be treated with antibiotics. Accordingly, patients living in

long-term healthcare facilities are generally older, and having higher chance of being exposed to increased antibiotics (Sunenshine and McDonald 2006).

The disease progression can vary from patient to patient, depending on their immune response to CDI. Those patients that produce high antibody titers to toxin A usually only develop diarrhea, and have a higher possibility of resolving without reoccurrence. On the contrary, failure to produce adequate antibodies to toxins results in increased risk for complications and recurrent infections (Kelly 1996, Kyne et al. 2001). Besides, asymptomatic carriers normally have high antibody titers to toxin A, and are unlikely to develop severe symptoms when exposed to antibiotics (Salcedo et al. 1997).

Prior to the emergence of hypervirulent strains of *C. difficile*, pregnant women share an unusual high occurrence rate of CDI, with some minor symptoms not involving hospitalization. Now there is an increased frequency and severity of disease is associated with CDI in peripartum women, leading to increased colectomies, stillbirths and maternal deaths (Rouphael et al. 2008). Those patients admitted to hospitals have increased rates of asymptomatic colonization despite of progress to infection. Cultures on a variety of surfaces in healthcare facilities have been tested and demonstrated high levels of *C. difficile* contamination (McFarland et al. 1989). In screenings of patients upon admission, it has been found that carriage rates have a range between 5.9 to 11%, which is higher than the normal distribution in adults of 2 to 3%. Infection rates differ among patient groups depending on other risks factors,

but overall the rate is between 4 to 21% in a non-outbreak environment. A study in one hospital demonstrated an acquisition rate of 13% for patients hospitalized for 1-2 weeks; the rate increased to 50% based on the hospitalized patients for more than a month (Calabi et al. 2002). Approximately 63% of these patients would become asymptomatic carriers. What's more, studies of outbreaks have found acquisition rates can rise to as high as 32%, especially when highly susceptible patients are involved (Barbut and Petit 2001). It is found that the time needed to treat patients, those who developed CDI while being treated for another issue at the same time, could be increased by 3.6 days in the hospital, at an estimated cost of over 1 billion dollars in the U.S. per year (Kyne et al. 2002).

### **1.7 Treatment for CDI**

The first step in treatment of CDI is to stop the current offending antibiotic if possible, or switch to another antibiotic with a narrower spectrum. Using this method, nearly 25% of diarrhea from mild CDI would be resolved without further complication (Barbut et al. 2000). Subsequently, supportive therapy should be followed to rehydrate and replace electrolytes, especially in patients with severe diarrhea. Antiperistaltic drug therapy should be avoided to limit patients' exposure to *C. difficile* toxins, which may result in the development of toxic megacolon (McFarland 2005). Because of the rise of hypervirulent strains, some physicians may treat with antibiotics until CDI has been ruled out by laboratory testing (Bartlett and Gerding 2008).

Clindamycin is an effective treatment for serious anaerobic infection, but was used so widely that it has been gradually losing its efficiency (Kabins and Spira 1975). To date, when diarrhea and colitis caused by *C. difficile* are severe, there are some other common effective treatments which are oral metronidazole and oral vancomycin (Kelly and LaMont 1998). Besides, ampicillin, amoxicillin, and cephalosporins are also some common alternatives concerned with *C. difficile* (Kelly and LaMont 1998).

*C. difficile* strains produce a binary toxin (CDT), apart from toxin A and toxin B, and they exhibit a resistance to fluroquinolones and erythromycin (Cartman et al. 2010). Moreover, treating asymptomatic carriers with metronidazole or vancomycin is not ideal, for the treatment may extend the carrier state (Johnson et al. 1992).

Antibiotics are regarded as the most important risk factor for *C. difficile*-associated diarrhea by reducing ‘colonization resistance’ of the bowel, allowing subsequent colonization, and infection with *C. difficile* (Johnson and Gerding 1998a). Thus, using proper antibiotic is of crucial importance, and is also the most effective treatment of *C. difficile* infection.

Besides, probiotics containing one or several living beneficial microbes have also been a popular treatment, either serving as addition to antibiotic therapy or as a replacement for antibiotic treatment. The advantages of probiotics are: multiple mechanisms of acting on pathogens, benefit to host immune system, survival to host colon, no drug interaction, and low risk to the patient, while the drawbacks of probiotics are: poor quality control, poor standardization, few clinical trials, possible

infections with immunocompromised patients, and sometimes adverse reactions in patients (McFarland 2009).

### **1.8 *C. difficile* in food**

*C. difficile* infection (CDI) essentially occurs in clinic environments, while the majority of patients infected by *C. difficile* are asymptomatic carriers, and one of the known risk of infection is sharing a hospital room with an infected patient (Johnson et al. 1990). However, in the community, *C. difficile* is increasingly found among young and relatively healthy individuals (Hensgens et al. 2012). In the environment, such as soil and water, *C. difficile* commonly exists. Nevertheless, its presence in numerous animals is also ubiquitous, and similar PCR ribotypes are found, particularly ribotype 027 and ribotype 078 (Rodriguez et al. 2013, Hensgens et al. 2012). Accordingly, there may be a potential for transmission from food to humans.

Community-associated *C. difficile* infection is increasingly regarded as a potential foodborne disease, especially in food animal. A study from USA, examining samples from stores in the Tuscon, Arizona area, found isolation of *C. difficile* from 37 of 88 samples, including ground beef (13/26), summer sausage (1/7), ground pork (3/7), braunschweiger (10/16), chorizo (3/10), pork sausage (3/13), and ground turkey (4/9) (Songer et al. 2009). Ribotype 078 was the majority strain, and the rest belonged to ribotype 027 (Songer et al. 2009).

Though infection with retail meat is most compelling, infection with other food products may be equally fatal, particularly for those that are not cooked before

eating. A research from South Wales described 71% of *C. difficile* isolates from vegetables were toxigenic (al Saif and Brazier 1996b). Reported CDIs associated with salad-used-vegetables have also been found in France and Scotland (Bakri et al. 2009, Eckert, Burghoffer, and Barbut 2013).

## **CHAPTER II. Prevalence and antibiotic resistance of *C. difficile* in lettuce**

### **2.1 Introduction**

*Clostridium difficile* (*C. difficile*), a species of Gram-positive, spore-forming, and anaerobic bacteria, is the causative reason of *Clostridium difficile*-associated diarrhea (CDAD) and can lead to more serious disease such as pseudomembranous colitis, toxic megacolon, and even death in humans (Monaghan et al. 2013).

Pathogenic *C. difficile* produces two protein exotoxins, toxin A, comprised of 2710 residues (308.0 kDa), and toxin B, comprised of 2366 residues (269.6 kDa) (Kelly and LaMont 1998). Toxin A and B (also called TcdA and TcdB), the primary makers of *Clostridium difficile* infection (CDI), belong to the large clostridial cytotoxins (LCT). In addition to toxin A and B, *C. difficile* strains produce a binary toxin, called C.



*difficile* toxin (CDT). However, only about 6% of *C. difficile* isolates produce the binary toxin, and these are toxinotype variants (Geric et al. 2004).

In earlier studies, toxin A was regarded as the predominant virulence factor, and toxin B alone, without the present of toxin A did not cause disease (1994, Pothoulakis et al. 1986) (Voth and Ballard 2005). As a result, the mechanism of toxin B in disease is not well explored as the role of toxin A. With the discoveries of some toxinA<sup>-</sup>toxinB<sup>+</sup> strains (King, Mackin, and Lyras 2015), toxin B was reported to contribute to the *C. difficile*-associated diseases, and it was regarded as the essential virulence contributor (Lyras, O'Connor, et al. 2009).

*C. difficile* infection (CDI) essentially has occurred in a clinic environment, however, community-associated *C. difficile* infection is increasingly regarded as a potential foodborne disease, especially in food animals (Rodriguez et al. 2014). Though infection with retail meat is most compelling but has not been proven (Rodriguez et al. 2013), infection with other food products may be equally fatal, particularly for those that are not cooked before eating (Weese 2010). Pathogenic *C. difficile* isolated from vegetables has been reported in Europe (al Saif and Brazier 1996b), while in United States, there is limited research focusing on ready-to-eat vegetable such as lettuce. Modified atmosphere packing and storage condition of lettuce could promote the growth of anaerobic bacteria such as *C. difficile* (Doulgeraki, Paramithiotis, and Nychas 2011). Furthermore, there are various possible sources of lettuce contamination with *C. difficile*, all of which are likely to be ultimately human

or animal, such as soil, fertilizer (manure), water, processing environments, and human hands (Simango 2006, Rodriguez et al. 2013, Weese 2010).

People are more likely to become infected with *C. difficile* with the use of antibiotics, not only because antibiotics disrupt the normal intestinal flora, resulting in *C. difficile* colonization (Kyne et al. 2002), but also *C. difficile* has been found to be resistance to several antibiotics (Owens et al. 2008, Gerding 2004). Antibiotics are used to treat bacterial infections, but some antibiotics are found to be ineffective in treating the infection of anaerobic bacteria including *C. difficile* (Lyerly, Krivan, and Wilkins 1988). Clindamycin is an effective treatment for serious anaerobic bacterial infections, but has been used so widely that it is now gradually losing its efficiency (Kabins and Spira 1975). To date, when diarrhea and colitis caused by *C. difficile* are severe, the common effective treatments are oral metronidazole and vancomycin (Kelly and LaMont 1998).

In this study we determined the prevalence and antibiotic resistance of *C. difficile* in lettuce.

## **2.2 Materials and Methods**

### **2.2.1 Sample preparation**

Lettuces, harvested in California, Arkansas, and Louisiana, were continuously purchased from retail stores and tested from September 2014 to March 2015. The lettuce samples were grown in Salinas, California; Bentonville, Arkansas and Baton Rouge, Louisiana. The types of lettuce sample purchased from California, Arkansas,

and Louisiana were iceberg lettuce, butter lettuce, and romaine lettuce, respectfully.

In all, 297 lettuce samples were tested, and for each state, 99 samples were tested (8 lettuce samples for per month in September, October, November 2014; 10 lettuce samples in December 2014; 15 lettuce samples in January 2015; 20 lettuce samples in February 2015; 30 lettuce samples in March 2015)

Brain Heart Infusion broth (BHI) (BD) supplemented with 0.1% sodium taurocolic acid and *C. difficile* selective supplement (Sigma-Aldrich), containing cefoxitin (8 µg/ ml) and D-cycloserine (250 µg/ ml), was used to enrich *C. difficile* isolates, for isolation from the lettuce samples. For each lettuce sample, 60 ml sterile BHI supplemented broth and 40 g lettuce were blended together in a filter bag; the collection from each sample was done in duplicate. Every filter bag was incubated anaerobically by a GasPak™ EZ Anaerobe Pouch System at 37 °C for 10 days.

### 2.2.2 Isolation *C. difficile*

After the samples were incubated for 10 days, the sample broth in the filter bag was transferred into sterile test tubes. To detect the presence of *C. difficile*, BBL™ *Clostridium difficile* Selective Agar (BD) plates were used, 2 plates per filter bag. The plates were reduced anaerobically under room temperature for 24 hours before use. Then 0.1 ml of the collected supernatant was streaked onto the selective plates under a certified bacteria safety hood and the inverted plates were incubated anaerobically, with the anaerobe pouch system mentioned above, at 37 °C for 48 hours. *C. difficile* colonies were identified by their morphological and fluorescence

properties under long wavelength UV (380 nm) within one hour in the presence of oxygen. The positive *C. difficile* colonies emitted a yellow fluorescence. For further research, the *C. difficile* colonies of each lettuce sample isolated from the *C. difficile* selective plates were collected and stored in  $-80^{\circ}\text{C}$  freezer.

### 2.2.3 DNA extraction

Right after the colonies of *C. difficile* were observed on the plates, DNA extraction was conducted according to the instructions of a commercial DNA extraction kit (MO-BIO UltraClean<sup>®</sup> Microbial DNA Isolation Kit). Three colonies from each plate were collected into a sterile 2 ml centrifuge tube. Then the microbial cells were resuspended in provided bead solution, they were added to a bead beating tube containing beads, followed by lysis solution. With a combination of heat, detergent, and mechanical force against specialized beads, the cellular components were lysed. *C. difficile* DNA was released from the lysed cells, and bound to a silica Spin Filter. After washing the filter several times, the DNA was recovered in the provided DNA-free Tris buffer. Extracted DNA was stored at  $-20^{\circ}\text{C}$  until real-time PCR was performed.

### 2.2.4 Real-time PCR assays for toxin A and B

Non-repeat regions on toxin A and toxin B genes are commonly chosen as amplifying-segments in real-time PCR assays. For toxin A detection assay, the primers and the probe described by Luna et al. were utilized (Luna et al. 2011); for toxin B detection, the real-time PCR method was performed with the primers and the probe

specific to determine the virulence of *C. difficile* isolates in lettuce, which is described by van den Berg et al (van den Berg et al. 2005)(Table 1). The total volume of each reaction mixture for the Real-time PCR was 25 µl. For the toxin A assay, each amplification mixture consisted 12.5 µl Bio-Rad iQ™ Supermix (2x), 0.6 µM forward primer (tcdAF), 0.6 µM reverse primer (tedAR), 0.1 µM hydrolysis probe (tcdATM), PCR grade water, and a 6.25 µl DNA sample. For the toxin B assay, each final reaction mixture included 12.5 µl Bio-Rad iQ™ Supermix (2x), 0.25 µl of 10 µM forward primer (398CLDs), 0.5 µl of 10 µM reverse primer (399CLDs), 0.5 µl of 10 µM 551CLD-tq-FAM probe, 0.25 µl of 0.1M MgCl<sub>2</sub>, 8.5 µl PCR water, and 2.5 µl DNA template. Amplification was performed using a Cepheid SmartCycler II system (Sunnyvale). The cycling program of the toxin A assay was as following: 1 cycle of 95°C for 10 min; 45 cycles of 95°C for 10 min, 57°C for 20 s, and 72°C for 10 s. For toxin B assay, after the reaction mixtures were initially heated for 3 minutes at 95 °C, they went through 45 cycles. Each cycle possessed a 30 s denaturation step at 94 °C, a 30 s annealing step at 57 °C, and a 30 s extension step at 72 °C. Positive and negative controls were run in each trial. The extracted DNA (2.5 µl) from a toxin A positive toxin B positive *C. difficile* strain (ATCC 43255) was employed as the positive control, and the PCR grade water (2.5 µl) was served as the negative control.

**Table 1.** Primers and probes for real-time PCR detection of *C. difficile* toxin A and B

Primers and probe	Nucleotide sequence (5'- 3')
-------------------	------------------------------

---

Toxin A	tcdAF	GGTAATAATTCAAAAGCGGCT
	tcdAR	AGCATCCGTATTAGCAGGTG
	tcdATM	FAM-AGCCTAATACAGCTATGGGTGCGAA- AMRA
Toxin B	398CLDs	GAAAGTCCAAGTTTACGCTCAAT
	399CLDas	GCTGCACCTAAACTTACACCA
	551CLD-tq-FAM	FAM-ACAGATGCAGCCAAAGTTGTTGAAT T-TAMRA

---

### 2.2.5 Antibiotic resistance detection

The standard NCCLS (National Committee for Clinical Laboratory Standards) broth microdilution MIC (minimal inhibitory concentration) test was performed for the toxigenic isolates to determine the effect of following antibiotics, clindamycin, vancomycin, metronidazole, erythromycin, cefotaxime. For each toxigenic isolates, the broth microdilution MIC test was conducted in duplicate. The Mueller-Hinton broth (BD) was used, and the pH was adjusted between 7.2 and 7.4. Within 15 min of adjusting the inoculum broth to the turbidity of a 0.5 McFarland standard, the inoculum suspension was diluted to a final concentration of  $5 \times 10^4$  CFU/ 0.1 ml well. Results were recorded after 20-24 h incubation, and NCCLS interpretive criteria was

used to interpret the results: clindamycin, susceptible,  $\leq 2$   $\mu\text{g/ml}$ , resistant,  $\geq 8$   $\mu\text{g/ml}$ ; vancomycin, susceptible,  $\leq 2$   $\mu\text{g/ml}$ , resistant,  $>2$   $\mu\text{g/m}$ ; metronidazole, susceptible,  $\leq 8$   $\mu\text{g/ml}$ , resistant,  $\geq 32$   $\mu\text{g/ml}$ ; erythromycin, susceptible,  $\leq 0.5$   $\mu\text{g/ml}$ , resistant,  $\geq 8$   $\mu\text{g/ml}$ ; cefotaxime, susceptible,  $\leq 8$   $\mu\text{g/ml}$ , resistant,  $\geq 64$   $\mu\text{g/ml}$ .

## 2.3 Results and Discussions

### 2.3.1 Isolation *C. difficile*

From *Clostridium difficile* Selective Agar (CDSA) test, 52 (52.5%) *C. difficile* isolates were detected in 99 California lettuce samples; 44 (44.4%) *C. difficile* isolates were detected 99 Arkansas lettuce samples; 61 (61.6%) *C. difficile* isolates in 99 Louisiana lettuce samples (Table 2). Since the selective plates do not have the ability to differ the toxigenic isolates from the non-toxigenic ones. The detection of toxin A and B was followed to identify the toxigenic strains.

**Table 2.** *Clostridium difficile* isolated from California, Arkansas, and Louisiana lettuce samples between September 2014 and March 2015

State		Sep	Oct	Nov	Dec	Jan	Feb	Mar	Total (%)
	tested								
California	PO	2	5	7	3	7	11	17	52 (52.5%)
	S								
	N	8	8	8	10	15	20	30	99
Arkansas	PO	0	5	7	2	8	6	16	44 (44.4%)

---

		S								
		N	8	8	8	10	15	20	30	99
Louisiana	PO	0	3	6	3	8	16	25	61 (61.6%)	
		S								
		N	8	8	8	10	15	20	30	99

---

POS, the number of the sample having positive result from CDSA test. N, the total number of the sample tested.

### 2.3.2 Real-time PCR assays for toxin A and B

Since naturally occurring toxin A positive B negative isolates have not been reported so far (Lyras, O'Connor, et al. 2009), to determine the prevalence of the *C. difficile* isolates found in lettuce samples, toxin B real-time PCR assay was conducted. According to the results from toxin B detection (Table 3), 15 *Clostridium difficile* toxigenic isolates were detected in 99 samples from California; 10 *Clostridium difficile* toxigenic isolates were detected in 99 samples from Arkansas; 16 *Clostridium difficile* toxigenic isolates were detected in 99 samples from Louisiana.

The samples were continuously purchased and tested from September 2014 to March 2015. To determine whether there is a close relationship between the temperatures of the months (Figure 5) and the frequency of the toxigenic isolates presence from California, Arkansas, and Louisiana, a linear regression model was tested. The p values of the results from California, Arkansas, and Louisiana were




0.645, 0.0561, and 0.6659 larger than 0.05. The hypothesis was denied, meaning there was no direct relationship between these two.

**Table 3.** The positive result from real-time PCR for toxin B detection of *C. difficile* isolates in California, Arkansas, and Louisiana between September 2014 and March 2015

State		Sep	Oct	Nov	Dec	Jan	Feb	Mar	Total
	tested								(%)
California	POS	2	1	3	1	0	5	3	15
									(15.2%)
	N	8	8	8	10	15	20	30	99
Arkansas	POS	0	2	1	1	2	4	0	10
									(10.1%)
	N	8	8	8	10	15	20	30	99
Louisiana	POS	0	2	0	1	0	11	2	16
									(16.2%)
	N	8	8	8	10	15	20	30	99

POS, the number of the sample having positive result from toxin B real-time PCR assay. N, the total number of the sample tested.



**Figure 5.** The growth temperature of the sample lettuces harvested from California, Arkansas, and Louisiana between September 2014 and March 2015.

The toxin A real-time PCR results were recorded, combined with the results from toxin B detection assay (Table 4). Overall, 41 toxigenic isolates were detected from 297 samples; and among the 41 toxigenic isolates, there were 7 toxin A negative toxin B positive isolates. The totally percentage of the toxigenic *C. difficile* isolates found in lettuce samples was 13.8%, this was higher than the other reported results (Al Saif and Brazier 1996a, Bakri et al. 2009, Metcalf et al. 2010, Rodriguez-Palacios, Ilic, and LeJeune 2014). Previous scientific studies have concentrated on testing several types of vegetables including lettuce for toxigenic *C. difficile*. A study conduction in 2014, tested 125 different vegetables that included 41 lettuce samples for toxigenic *C. difficile*. The vegetable samples were from several retail stores located in Ohio and had originated from several states in the USA and Mexico. The results of their study found 1 positive toxigenic *C. difficile* isolate in the 41 lettuce samples

tested. (Rodriguez-Palacios, Ilic, and LeJeune 2014). Another study, reported 7.5% *C. difficile* prevalence in ready-to-eat salad in Scotland, they collected 40 packaged lettuce samples over one month from 7 different supermarkets (Bakri et al. 2009). These previous studies detected lower *C. difficile* prevalence in lettuce than this study possibly due to a small sample size and purchase location. (Bakri et al. 2009, Al Saif and Brazier 1996a, Metcalf et al. 2010, Rodriguez-Palacios, Ilic, and LeJeune 2014).

In addition, contamination of lettuce with *C. difficile* spores would not only be due to attachment on the leaves from contaminated water or soil (Simango 2006), but also would widely exist in the downstream production chain including storage, transportation, and handling environments (Rodriguez et al. 2013). Since the same varieties and brand of lettuces tested for toxigenic *C. difficile* came from the same processor located in California, Arkansas, and Louisiana, if the processing environment was exposed to toxigenic *C. difficile* spores, it would largely increase the presence of the *C. difficile* spores on the lettuce samples and thus increase the prevalence.

**Table 4.** Real-time PCR profile of *C. difficile* isolates in lettuce samples among the states tested

State tested	Toxin A - Toxin B +	Toxin A + Toxin B+	Total positive samples (%)
California,	3	12	15 (15.1%)
n=99			

---

Arkansas, n=99	2	8	10 (10.1%)
Louisiana, n=99	2	14	16 (16.2%)
Total	7/297 (2.4%)	34/297 (11.4%)	41/297 (13.8%)

---

### 2.3.3 Antibiotic resistance detection

Five antibiotics, metronidazole, vancomycin, clindamycin, erythromycin, and cefotaxime (Table 5), were tested for the toxigenic *C. difficile* isolates. Among the antibiotics we tested, all the 41 isolates were resistant or intermediately resistant to all the 5 antibiotics, while 37 isolates and 26 isolates showed intermediately resistance to clindamycin and cefotaxime. The resistance and intermediately resistance properties of the isolates for clindamycin and cefotaxime were in accord with the findings from other *C. difficile* vegetable isolates (Bakri et al. 2009). However, metronidazole, vancomycin, and erythromycin did not have the susceptible effect to the isolates as being reported (Bakri et al. 2009, Metcalf et al. 2010). Since the antibiotic resistance property of *C. difficile* would vary depending on the location (Metcalf et al. 2010), the different antibiotics effect would be understandable. Since no antibiotic resistance pattern remain consistent enough to be used as a *C. difficile* strain marker (Tenover, Tickler, and Persing 2012), the different antibiotics effect in this study would be

understandable. Besides, two same toxigenic *C. difficile* isolates from the same kind of vegetable were reported to have different antibiotic susceptibility to a certain antibiotic (Metcalf et al. 2010).

**Table 5.** Susceptibility of the *C. difficile* isolates to 5 antibiotics

Agent	MIC ( $\mu\text{g/ml}$ )			No. (%) of isolates		
	Range	50%	90%	Susceptible	Intermediate	Resistant
Metronidazole	0.125-80	>80	>80	0 (0)	0 (0)	41 (100)
Vancomycin	0.25-4	4	>4	0 (0)	0 (0)	41 (100)
Clindamycin	1-16	4	8	0 (0)	37 (90.2)	4 (9.8)
Erythromycin	1-16	16	>16	0 (0)	0 (0)	41 (100)
Cefotaxime	6-64	12	24	0 (0)	26 (63.4)	15 (36.6)

50%, the antibiotic concentration when 50% growth of the tested *C. difficile* isolate inhibited. 90%, the antibiotic concentration when 90% growth of the tested *C. difficile* isolate inhibited.

## 2.4 Conclusions

The *C. difficile* isolated from the retail lettuce has a high possibility to be toxigenic. Although the public health relevance is still unclear, consumption retail vegetables as salad vegetable or without high-temperature processed might be a source of *C. difficile* infection. Treated with five different antibiotics, the *C. difficile* sample isolates expressed strong resistance to metronidazole, vancomycin, and erythromycin. This present research contributes in revealing a possible source of community-associated *C. difficile* infection.

## REFERENCES

1994. "Treatment of Clostridium difficile associated diarrhea and colitis with an oral preparation of teicoplanin; a dose finding study. The Swedish CDAD Study Group." *Scand J Infect Dis* 26 (3):309-16. doi: 10.3109/00365549409011800.
- Aktories, Klaus, Ulrich Weller, and Gursharan S Chhatwal. 1987. "Clostridium botulinum type C produces a novel ADP - ribosyltransferase distinct from botulinum C2 toxin." *FEBS letters* 212 (1):109-113.
- Al Saif, N, and JS Brazier. 1996a. "The distribution of Clostridium difficile in the environment of South Wales." *Journal of Medical Microbiology* 45 (2):133-137.
- al Saif, N., and J. S. Brazier. 1996b. "The distribution of Clostridium difficile in the environment of South Wales." *J Med Microbiol* 45 (2):133-7.
- Arnon, S. S., D. C. Mills, P. A. Day, R. V. Henrickson, N. M. Sullivan, and T. D. Wilkins. 1984. "Rapid death of infant rhesus monkeys injected with Clostridium difficile toxins A and B: physiologic and pathologic basis." *J Pediatr* 104 (1):34-40.
- Bakri, M. M., D. J. Brown, J. P. Butcher, and A. D. Sutherland. 2009. "Clostridium difficile in ready-to-eat salads, Scotland." *Emerg Infect Dis* 15 (5):817-8. doi: 10.3201/eid1505.081186.
- Banno, Y., T. Kobayashi, H. Kono, K. Watanabe, K. Ueno, and Y. Nozawa. 1984. "Biochemical characterization and biologic actions of two toxins (D-1 and D-2) from Clostridium difficile." *Rev Infect Dis* 6 Suppl 1:S11-20.
- Barbut, F, and J - C Petit. 2001. "Epidemiology of Clostridium difficile - associated infections." *Clinical Microbiology and Infection* 7 (8):405-410.
- Barbut, Frédéric, Anne Richard, Kheira Hamadi, Valérie Chomette, Béatrice Burghoffer, and Jean-Claude Petit. 2000. "Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea." *Journal of clinical microbiology* 38 (6):2386-2388.
- Bartlett, JG, TEW Chang, M Gurwith, SL Gorbach, and AB Onderdonk. 1978a. "Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia." *New England Journal of Medicine*:531-534.

- Bartlett, John G. 2002. "Antibiotic-associated diarrhea." *New England journal of medicine* 346 (5):334-339.
- Bartlett, John G, Te Wen Chang, Marc Gurwith, Sherwood L Gorbach, and Andrew B Onderdonk. 1978b. "Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia." *New England Journal of Medicine* 298 (10):531-534.
- Bartlett, John G, and Dale N Gerding. 2008. "Clinical recognition and diagnosis of Clostridium difficile infection." *Clinical Infectious Diseases* 46 (Supplement 1):S12-S18.
- Belyi, Yury, and Klaus Aktories. 2010. "Bacterial toxin and effector glycosyltransferases." *Biochimica et Biophysica Acta (BBA)-General Subjects* 1800 (2):134-143.
- Best, Emma L, Warren N Fawley, Peter Parnell, and Mark H Wilcox. 2010. "The potential for airborne dispersal of Clostridium difficile from symptomatic patients." *Clinical Infectious Diseases* 50 (11):1450-1457.
- Bignardi, GE. 1998. "Risk factors for Clostridium difficile infection." *Journal of Hospital Infection* 40 (1):1-15.
- Calabi, Emanuela, Franco Calabi, Alan D Phillips, and Neil F Fairweather. 2002. "Binding of Clostridium difficile surface layer proteins to gastrointestinal tissues." *Infection and immunity* 70 (10):5770-5778.
- Carling, Philip, Teresa Fung, Ann Killion, Norma Terrin, and Michael Barza. 2003. "Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years." *Infection Control & Hospital Epidemiology* 24 (09):699-706.
- Cartman, S. T., J. T. Heap, S. A. Kuehne, A. Cockayne, and N. P. Minton. 2010. "The emergence of 'hypervirulence' in Clostridium difficile." *Int J Med Microbiol* 300 (6):387-95. doi: 10.1016/j.ijmm.2010.04.008.
- Chaves-Olarte, E., M. Weidmann, C. Eichel-Streiber, and M. Thelestam. 1997. "Toxins A and B from Clostridium difficile differ with respect to enzymatic potencies, cellular substrate specificities, and surface binding to cultured cells." *J Clin Invest* 100 (7):1734-41. doi: 10.1172/JCI119698.

- De Hoon, Michiel JL, Patrick Eichenberger, and Dennis Vitkup. 2010. "Hierarchical evolution of the bacterial sporulation network." *Current biology* 20 (17):R735-R745.
- Donskey, Curtis J. 2010. "Preventing transmission of *Clostridium difficile*: is the answer blowing in the wind?" *Clinical Infectious Diseases* 50 (11):1458-1461.
- Doulgeraki, Agapi I, Spiros Paramithiotis, and George-John E Nychas. 2011. "Characterization of the Enterobacteriaceae community that developed during storage of minced beef under aerobic or modified atmosphere packaging conditions." *International journal of food microbiology* 145 (1):77-83.
- Drudy, Denise, Séamus Fanning, and Lorraine Kyne. 2007. "Toxin A-negative, toxin B-positive *Clostridium difficile*." *International Journal of Infectious Diseases* 11 (1):5-10.
- Eckert, C., B. Burghoffer, and F. Barbut. 2013. "Contamination of ready-to-eat raw vegetables with *Clostridium difficile* in France." *J Med Microbiol* 62 (Pt 9):1435-8. doi: 10.1099/jmm.0.056358-0.
- Gerding, Dale N. 2004. "Clindamycin, cephalosporins, fluoroquinolones, and *Clostridium difficile*–associated diarrhea: this is an antimicrobial resistance problem." *Clinical infectious diseases* 38 (5):646-648.
- Gerding, Dale N, Carlene A Muto, and Robert C Owens. 2008. "Measures to control and prevent *Clostridium difficile* infection." *Clinical Infectious Diseases* 46 (Supplement 1):S43-S49.
- Geric, B., M. Rupnik, D. N. Gerding, M. Grabnar, and S. Johnson. 2004. "Distribution of *Clostridium difficile* variant toxinotypes and strains with binary toxin genes among clinical isolates in an American hospital." *J Med Microbiol* 53 (Pt 9):887-94.
- Giannasca, Paul J, and Michel Warny. 2004. "Active and passive immunization against *Clostridium difficile* diarrhea and colitis." *Vaccine* 22 (7):848-856.
- Hall, IC, and E O'Toole. 1935. "Intestinal flora in new-born infants: with a description of a new pathogenic anaerobe, *Bacillus difficilis*." *Am J Dis Child*:390-402.
- Hensgens, M. P., E. C. Keessen, M. M. Squire, T. V. Riley, M. G. Koene, E. de Boer, L. J. Lipman, E. J. Kuijper, Microbiology European Society of Clinical, and



- difficile Infectious Diseases Study Group for Clostridium. 2012. "Clostridium difficile infection in the community: a zoonotic disease?" *Clin Microbiol Infect* 18 (7):635-45. doi: 10.1111/j.1469-0691.2012.03853.x.
- Hundsberger, T., V. Braun, M. Weidmann, P. Leukel, M. Sauerborn, and C. von Eichel-Streiber. 1997. "Transcription analysis of the genes tcdA-E of the pathogenicity locus of Clostridium difficile." *Eur J Biochem* 244 (3):735-42.
- Jank, Thomas, Torsten Giesemann, and Klaus Aktories. 2007. "Rho-glucosylating Clostridium difficile toxins A and B: new insights into structure and function." *Glycobiology* 17 (4):15R-22R.
- Johnson, S., C. R. Clabots, F. V. Linn, M. M. Olson, L. R. Peterson, and D. N. Gerding. 1990. "Nosocomial Clostridium difficile colonisation and disease." *Lancet* 336 (8707):97-100.
- Johnson, S., and D. N. Gerding. 1998a. "Clostridium difficile--associated diarrhea." *Clin Infect Dis* 26 (5):1027-34; quiz 1035-6.
- Johnson, S., S. R. Homann, K. M. Bettin, J. N. Quick, C. R. Clabots, L. R. Peterson, and D. N. Gerding. 1992. "Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial." *Ann Intern Med* 117 (4):297-302.
- Johnson, Stuart, and Dale N Gerding. 1998b. "Clostridium difficile-associated diarrhea." *Clinical infectious diseases*:1027-1034.
- Kabins, S. A., and T. J. Spira. 1975. "Outbreak of clindamycin-associated colitis." *Ann Intern Med* 83 (6):830-1.
- Kato, Haru, Naoki Kato, Kunitomo Watanabe, Kazue Ueno, Hiroshi Ushijima, Shintaro Hashira, and Toshiaki Abe. 1994. "Application of typing by pulsed-field gel electrophoresis to the study of Clostridium difficile in a neonatal intensive care unit." *Journal of clinical microbiology* 32 (9):2067-2070.
- Kelly, C. P., and J. T. LaMont. 1998. "Clostridium difficile infection." *Annu Rev Med* 49:375-90. doi: 10.1146/annurev.med.49.1.375.
- Kelly, Ciarán P. 1996. "Immune response to Clostridium difficile infection." *European journal of gastroenterology & hepatology* 8 (11):1048-1053.

- Kelly, Ciaran P, Charalabos Pothoulakis, and J Thomas LaMont. 1994. "Clostridium difficile colitis." *New England Journal of Medicine* 330 (4):257-262.
- King, A. M., K. E. Mackin, and D. Lyras. 2015. "Emergence of toxin A-negative, toxin B-positive Clostridium difficile strains: epidemiological and clinical considerations." *Future Microbiol* 10 (1):1-4. doi: 10.2217/fmb.14.115.
- Kyne, Lorraine, Mary Beth Hamel, Rajashekhar Polavaram, and Ciarán P Kelly. 2002. "Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile." *Clinical Infectious Diseases* 34 (3):346-353.
- Kyne, Lorraine, Michel Warny, Amir Qamar, and Ciarán P Kelly. 2001. "Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea." *The Lancet* 357 (9251):189-193.
- Lawley, Trevor D, Nicholas J Croucher, Lu Yu, Simon Clare, Mohammed Sebahia, David Goulding, Derek J Pickard, Julian Parkhill, Jyoti Choudhary, and Gordon Dougan. 2009. "Proteomic and genomic characterization of highly infectious Clostridium difficile 630 spores." *Journal of bacteriology* 191 (17):5377-5386.
- Luna, R. A., B. L. Boyanton, Jr., S. Mehta, E. M. Courtney, C. R. Webb, P. A. Revell, and J. Versalovic. 2011. "Rapid stool-based diagnosis of Clostridium difficile infection by real-time PCR in a children's hospital." *J Clin Microbiol* 49 (3):851-7. doi: 10.1128/JCM.01983-10.
- Lyerly, D. M., H. C. Krivan, and T. D. Wilkins. 1988. "Clostridium difficile: its disease and toxins." *Clin Microbiol Rev* 1 (1):1-18.
- Lyras, D., J. R. O'Connor, P. M. Howarth, S. P. Sambol, G. P. Carter, T. Phumoonna, R. Poon, V. Adams, G. Vedantam, S. Johnson, D. N. Gerding, and J. I. Rood. 2009. "Toxin B is essential for virulence of Clostridium difficile." *Nature* 458 (7242):1176-9. doi: 10.1038/nature07822.
- Lyras, Dena, Jennifer R O'Connor, Pauline M Howarth, Susan P Sambol, Glen P Carter, Tongted Phumoonna, Rachael Poon, Vicki Adams, Gayatri Vedantam, and Stuart Johnson. 2009. "Toxin B is essential for virulence of Clostridium difficile." *Nature* 458 (7242):1176-1179.
- McFarland, Lynne V. 2005. "Alternative treatments for Clostridium difficile disease: what really works?" *Journal of medical microbiology* 54 (2):101-111.

- McFarland, Lynne V. 2009. "Evidence-based review of probiotics for antibiotic-associated diarrhea and *Clostridium difficile* infections." *Anaerobe* 15 (6):274-280.
- McFarland, Lynne V, Maury E Mulligan, Richard YY Kwok, and Walter E Stamm. 1989. "Nosocomial acquisition of *Clostridium difficile* infection." *New England journal of medicine* 320 (4):204-210.
- Metcalf, D. S., M. C. Costa, W. M. V. Dew, and J. S. Weese. 2010. "*Clostridium difficile* in vegetables, Canada." *Letters in Applied Microbiology* 51 (5):600-602. doi: 10.1111/j.1472-765X.2010.02933.x.
- Mitchell, T. J., J. M. Ketley, S. C. Haslam, J. Stephen, D. W. Burdon, D. C. Candy, and R. Daniel. 1986a. "Effect of toxin A and B of *Clostridium difficile* on rabbit ileum and colon." *Gut* 27 (1):78-85.
- Mitchell, TJ, JM Ketley, SC Haslam, J Stephen, DW Burdon, DC Candy, and R Daniel. 1986b. "Effect of toxin A and B of *Clostridium difficile* on rabbit ileum and colon." *Gut* 27 (1):78-85.
- Monaghan, Tanya M, Adrian Robins, Alan Knox, Herbert F Sewell, and Yashwant R Mahida. 2013. "Circulating antibody and memory B-cell responses to *C. difficile* toxins A and B in patients with *C. difficile*-associated diarrhoea, inflammatory bowel disease and cystic fibrosis." *PloS one* 8 (9):e74452.
- Nelson, David E, Steven B Auerbach, Aldona L Baltch, Ethel Desjardin, Consuelo Beck-Sague, Carol Rheal, Raymond P Smith, and William R Jarvis. 1994. "Epidemic *Clostridium difficile*-associated diarrhea: role of second- and third-generation cephalosporins." *Infection Control & Hospital Epidemiology* 15 (02):88-94.
- Owens, Robert C, Curtis J Donskey, Robert P Gaynes, Vivian G Loo, and Carlene A Muto. 2008. "Antimicrobial-associated risk factors for *Clostridium difficile* infection." *Clinical Infectious Diseases* 46 (Supplement 1):S19-S31.
- Paredes, Carlos J, Keith V Alsaker, and Eleftherios T Papoutsakis. 2005. "A comparative genomic view of clostridial sporulation and physiology." *Nature Reviews Microbiology* 3 (12):969-978.
- Pear, Suzanne M, Theresa H Williamson, Kristine M Bettin, Dale N Gerding, and John N Galgiani. 1994. "Decrease in nosocomial *Clostridium*

- difficile-associated diarrhea by restricting clindamycin use." *Annals of Internal Medicine* 120 (4):272-277.
- Perelle, Sylvie, Maryse Gibert, Pierre Bourlioux, Gerard Corthier, and Michel R Popoff. 1997. "Production of a complete binary toxin (actin-specific ADP-ribosyltransferase) by *Clostridium difficile* CD196." *Infection and immunity* 65 (4):1402-1407.
- Popoff, MICHEL R, EJ Rubin, DM Gill, and P Boquet. 1988. "Actin-specific ADP-ribosyltransferase produced by a *Clostridium difficile* strain." *Infection and immunity* 56 (9):2299-2306.
- Pothoulakis, C., G. Triadafilopoulos, M. Clark, C. Franzblau, and J. T. LaMont. 1986. "Clostridium difficile cytotoxin inhibits protein synthesis in fibroblasts and intestinal mucosa." *Gastroenterology* 91 (5):1147-53.
- Rihn, B., G. Beck, H. Monteil, F. Lecerf, and R. Girardot. 1985. "Effect of the cytotoxin of *Clostridium difficile* on cultured hepatoma cells." *Biol Cell* 53 (1):23-32.
- Roberts, Katherine, Caroline F Smith, Anna M Snelling, Kevin G Kerr, Kathleen R Banfield, P Andrew Sleight, and Clive B Beggs. 2008. "Aerial dissemination of *Clostridium difficile* spores." *BMC infectious diseases* 8 (1):1.
- Rodriguez-Palacios, A., S. Ilic, and J. T. LeJeune. 2014. "Clostridium difficile with Moxifloxacin/Clindamycin Resistance in Vegetables in Ohio, USA, and Prevalence Meta-Analysis." *J Pathog* 2014:158601. doi: 10.1155/2014/158601.
- Rodriguez, C., V. Avesani, J. Van Broeck, B. Taminiau, M. Delmee, and G. Daube. 2013. "Presence of *Clostridium difficile* in pigs and cattle intestinal contents and carcass contamination at the slaughterhouse in Belgium." *Int J Food Microbiol* 166 (2):256-62. doi: 10.1016/j.ijfoodmicro.2013.07.017.
- Rodriguez, C., B. Taminiau, V. Avesani, J. Van Broeck, M. Delmee, and G. Daube. 2014. "Multilocus sequence typing analysis and antibiotic resistance of *Clostridium difficile* strains isolated from retail meat and humans in Belgium." *Food Microbiol* 42:166-71. doi: 10.1016/j.fm.2014.03.021.
- Rouphael, Nadine G, Judith A O'Donnell, Julu Bhatnagar, Felicia Lewis, Philip M Polgreen, Susan Beekmann, Jeannette Guarner, George E Killgore, Becky Coffman, and Jennifer Campbell. 2008. "Clostridium difficile-associated

- diarrhea: an emerging threat to pregnant women." *American journal of obstetrics and gynecology* 198 (6):635. e1-635. e6.
- Salcedo, J, S Keates, C Pothoulakis, M Warny, I Castagliuolo, JT LaMont, and CP Kelly. 1997. "Intravenous immunoglobulin therapy for severe *Clostridium difficile* colitis." *Gut* 41 (3):366-370.
- Schwan, Carsten, Bärbel Stecher, Tina Tzivelekidis, Marco van Ham, Manfred Rohde, Wolf-Dietrich Hardt, Jürgen Wehland, and Klaus Aktories. 2009. "*Clostridium difficile* toxin CDT induces formation of microtubule-based protrusions and increases adherence of bacteria." *PLoS Pathog* 5 (10):e1000626.
- Setlow, Peter. 2007. "I will survive: DNA protection in bacterial spores." *Trends in microbiology* 15 (4):172-180.
- Simango, Clifford. 2006. "Prevalence of *Clostridium difficile* in the environment in a rural community in Zimbabwe." *Transactions of the Royal Society of Tropical Medicine and Hygiene* 100 (12):1146-1150.
- Simor, Andrew E, Suzanne F Bradley, Larry J Strausbaugh, Kent Crossley, and Lindsay E Nicolle. 2002. "*Clostridium difficile* in long-term-care facilities for the elderly." *Infection Control & Hospital Epidemiology* 23 (11):696-703.
- Simpson, LL, BG Stiles, H Zepeda, and TD Wilkins. 1989. "Production by *Clostridium spiroforme* of an iotalike toxin that possesses mono (ADP-ribosyl) transferase activity: identification of a novel class of ADP-ribosyltransferases." *Infection and immunity* 57 (1):255-261.
- Snyder, MD. 1937. "Further studies on *Bacillus difficilis*." *J Infect Dis*:223.
- Songer, J. G., H. T. Trinh, G. E. Killgore, A. D. Thompson, L. C. McDonald, and B. M. Limbago. 2009. "*Clostridium difficile* in retail meat products, USA, 2007." *Emerg Infect Dis* 15 (5):819-21. doi: 10.3201/eid1505.081071.
- Stiles, Bradley G, and Tracy D Wilkins. 1986. "*Clostridium perfringens* iota toxin: synergism between two proteins." *Toxicon* 24 (8):767-773.
- Stubbs, Simon, Maja Rupnik, Maryse Gibert, Jon Brazier, Brian Duerden, and Michel Popoff. 2000. "Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of *Clostridium difficile*." *FEMS Microbiology Letters* 186 (2):307-312.

- Sullivan, N. M., S. Pellett, and T. D. Wilkins. 1982. "Purification and characterization of toxins A and B of *Clostridium difficile*." *Infect Immun* 35 (3):1032-40.
- Sunenshine, Rebecca H, and L Clifford McDonald. 2006. "Clostridium difficile-associated disease: new challenges from an established pathogen." *Cleveland Clinic journal of medicine* 73 (2):187.
- TABAQCHALI, SOAD, SHEILA O'FARRELL, JQ Nash, and M Wilks. 1984. "Vaginal carriage and neonatal acquisition of *Clostridium difficile*." *Journal of medical microbiology* 18 (1):47-53.
- Taylor, NS, GM Thorne, and JG Bartlett. 1981. "Comparison of two toxins produced by *Clostridium difficile*." *Infection and immunity* 34 (3):1036-1043.
- Tenover, Fred C, Isabella A Tickler, and David H Persing. 2012. "Antimicrobial-resistant strains of *Clostridium difficile* from North America." *Antimicrobial agents and chemotherapy* 56 (6):2929-2932.
- Torres, J. F., and I. Lonroth. 1989. "Production, purification and characterization of *Clostridium difficile* toxic proteins different from toxin A and from toxin B." *Biochim Biophys Acta* 998 (2):151-7.
- Underwood, Sarah, Shuang Guan, Vinod Vijayasubhash, Simon D Baines, Luke Graham, Richard J Lewis, Mark H Wilcox, and Keith Stephenson. 2009. "Characterization of the sporulation initiation pathway of *Clostridium difficile* and its role in toxin production." *Journal of bacteriology* 191 (23):7296-7305.
- van den Berg, R. J., L. S. Bruijnesteijn van Coppenraet, H. J. Gerritsen, H. P. Endtz, E. R. van der Vorm, and E. J. Kuijper. 2005. "Prospective multicenter evaluation of a new immunoassay and real-time PCR for rapid diagnosis of *Clostridium difficile*-associated diarrhea in hospitalized patients." *J Clin Microbiol* 43 (10):5338-40. doi: 10.1128/JCM.43.10.5338-5340.2005.
- Voth, D. E., and J. D. Ballard. 2005. "Clostridium difficile toxins: mechanism of action and role in disease." *Clin Microbiol Rev* 18 (2):247-63. doi: 10.1128/CMR.18.2.247-263.2005.
- Warny, M., J. Pepin, A. Fang, G. Killgore, A. Thompson, J. Brazier, E. Frost, and L. C. McDonald. 2005. "Toxin production by an emerging strain of *Clostridium difficile* associated with outbreaks of severe disease in North America and

Europe." *Lancet* 366 (9491):1079-84. doi:  
10.1016/S0140-6736(05)67420-X.

Weese, JS. 2010. "Clostridium difficile in food—innocent bystander or serious threat?" *Clinical Microbiology and Infection* 16 (1):3-10.

Yamakawa, K, T Karasawa, S Ikoma, and S Nakamura. 1996. "Enhancement of Clostridium difficile toxin production in biotin-limited conditions." *Journal of medical microbiology* 44 (2):111-114.

## VITA

Yi Han, born and raised in Shanghai, China, received her bachelor's degree in Biotechnology at Tongji University. To pursue her passion in food science, she enrolled as a food science master student at Louisiana State University in 2013, emphasis on food microbiology. She conducted her research on *Clostridium difficile* in retail lettuces. She is a candidate to receive her master of science degree in August 2016.